Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
China flag China · Delayed Price · Currency is CNY
29.12
+0.14 (0.48%)
Apr 17, 2026, 3:00 PM CST

SHA:688319 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
700.13586.1494.29546.68485.29
Other Revenue
4.032.751.830.81.86
704.16588.86496.12547.48487.15
Revenue Growth (YoY)
19.58%18.69%-9.38%12.38%52.18%
Cost of Revenue
63.1729.7736.7343.0128.36
Gross Profit
641559.09459.39504.48458.79
Selling, General & Admin
456.1389.32336.12352.06296.33
Research & Development
132.9134.23114.73121.9956.36
Other Operating Expenses
6.053.723.323.553.21
Operating Expenses
608.26537.47455.89489.78364.9
Operating Income
32.7321.623.5114.793.89
Interest Expense
-14.99-14.46-7.18-5.07-1.23
Interest & Investment Income
1.15.363.67.555.19
Currency Exchange Gain (Loss)
-0.01----
Other Non Operating Income (Expenses)
0.09-0.250.07-0.21-0.19
EBT Excluding Unusual Items
18.9212.28-0.0116.9797.67
Gain (Loss) on Sale of Assets
0.01-0.03-0.15-0.15-0.05
Other Unusual Items
12.9610.0615.7726.839.57
Pretax Income
31.8922.315.6243.65107.19
Income Tax Expense
9.996.584.1817.07-0.77
Earnings From Continuing Operations
21.915.7211.4426.58107.96
Minority Interest in Earnings
0.365.046.11--
Net Income
22.2620.7617.5626.58107.96
Net Income to Common
22.2620.7617.5626.58107.96
Net Income Growth
7.24%18.24%-33.95%-75.38%198.82%
Shares Outstanding (Basic)
405405405405385
Shares Outstanding (Diluted)
405405405405385
Shares Change (YoY)
0.01%-0.01%0.07%5.22%5.61%
EPS (Basic)
0.050.050.040.070.28
EPS (Diluted)
0.050.050.040.070.28
EPS Growth
7.23%18.25%-33.99%-76.61%182.95%
Free Cash Flow
6.68-217.05-125.88-225.24-29.75
Free Cash Flow Per Share
0.02-0.54-0.31-0.56-0.08
Dividend Per Share
--0.038--
Gross Margin
91.03%94.94%92.60%92.14%94.18%
Operating Margin
4.65%3.67%0.71%2.69%19.27%
Profit Margin
3.16%3.52%3.54%4.85%22.16%
Free Cash Flow Margin
0.95%-36.86%-25.37%-41.14%-6.11%
EBITDA
66.250.430.6240116.93
EBITDA Margin
9.40%8.56%6.17%7.31%24.00%
D&A For EBITDA
33.4728.7827.1125.323.04
EBIT
32.7321.623.5114.793.89
EBIT Margin
4.65%3.67%0.71%2.69%19.27%
Effective Tax Rate
31.34%29.52%26.74%39.11%-
Revenue as Reported
704.16588.86496.12547.48487.15
Advertising Expenses
331.88264.73224.9248.75212.96
Source: S&P Global Market Intelligence. Standard template. Financial Sources.